Cargando…

Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab

Ustekinumab for the treatment of psoriasis is currently administered in a standard dosing regimen. However, some patients tend to benefit from alternative dosing regimens, a step toward personalized medicine. METHODS: To investigate the role of ustekinumab serum concentrations, anti-ustekinumab anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Keyser, Eline, Busard, Celine I., Lanssens, Sven, Meuleman, Lieve, Hutten, Barbara A., Costanzo, Antonio, van den Reek, Juul M., Zweegers, Jeffrey, Lambert, Jo, Spuls, Phyllis I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Therapeutic Drug Monitoring 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752798/ https://www.ncbi.nlm.nih.gov/pubmed/31107404 http://dx.doi.org/10.1097/FTD.0000000000000646

Ejemplares similares

Clinical response correlates with 4‐week postinjection ustekinumab concentrations in patients with moderate‐to‐severe psoriasis
por: Van den Berghe, N., et al.
Publicado: (2019)

Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial
por: Busard, Celine, et al.
Publicado: (2017)

Erratum to: Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial
por: Busard, Celine, et al.
Publicado: (2017)

HLA-Cw1 and Psoriasis
por: Huang, Yi-Wei, et al.
Publicado: (2021)

The role of HLA-Cw6 in psoriasis and psoriatic arthritis
por: Owczarek, Witold
Publicado: (2022)

Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis
por: Anzengruber, Florian, et al.
Publicado: (2018)

HLA-Cw6 Status and Treatment Responses Between Psoriasis Patients
por: Temel, Berkay, et al.
Publicado: (2021)

The HLA-Cw12 Allele Is an Important Susceptibility Allele for Psoriasis and Is Associated with Resistant Psoriasis in the Turkish Population
por: Onsun, Nahide, et al.
Publicado: (2019)

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
por: van der Schoot, Lara S., et al.
Publicado: (2022)

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab
por: Papoutsaki, Marina, et al.
Publicado: (2009)

Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis
por: Ho, P Y P C, et al.
Publicado: (2008)

Correlation of HLA-Cw6 Positivity with Clinical Characteristics and Treatment Efficacy in Korean Patients with Psoriasis
por: Kim, So Mim, et al.
Publicado: (2022)

Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice
por: ATALAY, Selma, et al.
Publicado: (2021)

Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)

Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis
por: Olabi, Bayanne, et al.
Publicado: (2020)

Increased Risk of Psoriasis due to combined effect of HLA-Cw6 and LCE3 risk alleles in Indian population
por: Chandra, Aditi, et al.
Publicado: (2016)

Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
por: van Muijen, Marloes E., et al.
Publicado: (2021)

Paradoxical Flare of Psoriasis after Ustekinumab Therapy
por: Lee, Ho Yeol, et al.
Publicado: (2017)

Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis
por: Lynch, Maeve, et al.
Publicado: (2017)

Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study
por: ATALAY, Selma, et al.
Publicado: (2020)

In silico characterization of immunogenic epitopes presented by HLA-Cw*0401
por: Tong, Joo Chuan, et al.
Publicado: (2007)

The HLA-Cw6 Dilemma: Is It Really an Outcome Predictor in Psoriasis Patients under Biologic Therapy? A Monocentric Retrospective Analysis
por: Burlando, Martina, et al.
Publicado: (2020)

Frequency of streptococcal upper respiratory tract infections and HLA-Cw*06 allele in 70 patients with guttate psoriasis from northern Poland
por: Maciejewska-Radomska, Agata, et al.
Publicado: (2015)

Psoriasis Patients with Specific HLA-Cw Alleles and Lower Plasma IL-17 Level Show Improved Response to Topical Lindioil Treatment
por: Lin, Yin-Ku, et al.
Publicado: (2022)

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
por: van der Schoot, L.S., et al.
Publicado: (2023)

Potential role of ustekinumab in the treatment of chronic plaque psoriasis
por: Mercuri, Santo Raffaele, et al.
Publicado: (2010)

Recalcitrant psoriasis responding to new bilogic drug: Ustekinumab
por: Husein-ElAhmed, Husein, et al.
Publicado: (2013)

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
por: Tsakok, Teresa, et al.
Publicado: (2019)

Genome-Wide Association Study of Ustekinumab Response in Psoriasis
por: Connell, William T., et al.
Publicado: (2022)

Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations
por: Yang, Seungkeol, et al.
Publicado: (2021)

The impact of HLA-Cw*12:02 on control of HIV-1 infection
por: Koyanagi, M, et al.
Publicado: (2012)

Analysis of the expression of KIR and HLA-Cw in a Northeast Han population
por: HAN, YU, et al.
Publicado: (2013)

Inheritance of HLA-Cw7 Associated With Autism Spectrum Disorder (ASD)
por: Harville, Terry, et al.
Publicado: (2019)

Ustekinumab Treatment of Erythrodermic Psoriasis Occurring after Physical Stress: A Report of Two Cases
por: Saraceno, Rosita, et al.
Publicado: (2013)

Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
por: Lambert, Jo, et al.
Publicado: (2021)

HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study
por: Mallbris, Lotus, et al.
Publicado: (2009)

Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis
por: Elberdín, Laida, et al.
Publicado: (2022)

Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis
por: Krulig, Eliana, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_frtevpi2itohc4fsha7t764d6a